Clinical Trial

Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a multicenter, open-label Phase Ia/b study on the safety and efficacy of the combination of NMS-03305293 and topotecan in patients with recurrent ovarian cancer, with dose-limiting toxicity (DLT) escalation. The aim of this study is to determine the safety and tolerability, as well as to evaluate the anti-tumor efficacy and pharmacokinetics of NMS-03305293 in combination with topotecan.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2025-04-09; most recent amendment 2026-05-25.
Status change: Not Yet Recruiting → Recruiting 2025-08-20
Trial Details
NCT Number NCT06930755
Lead Sponsor Nerviano Medical Sciences
Conditions Ovarian Cancer
Enrollment 24 participants
Start Date 2026-05-13
Primary Completion 2027-05-31 (estimated)
Study Completion 2027-09-26 (estimated)
Updated on ClinicalTrials.gov 2026-05-28